{"name":"Milestone Pharmaceuticals","slug":"milestone","ticker":"MIST","exchange":"NASDAQ","domain":"milestonepharma.com","description":"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.","hq":"Montreal, Canada","founded":0,"employees":"38","ceo":"Joseph Oliveto","sector":"Cardiology / Specialty Pharma","stockPrice":1.55,"stockChange":-0.17,"stockChangePercent":-9.88,"marketCap":"$186M","metrics":{"revenue":1546000,"revenueGrowth":0,"grossMargin":100,"rdSpend":18108000,"netIncome":-63058000,"cash":105960000,"dividendYield":0,"peRatio":-1.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"etripamil patent cliff ($0.0B at risk)","drug":"etripamil","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etripamil NS","genericName":"Etripamil NS","slug":"etripamil-ns","indication":"Acute conversion of supraventricular tachycardia to normal sinus rhythm","status":"phase_3"}]}],"pipeline":[{"name":"Etripamil NS","genericName":"Etripamil NS","slug":"etripamil-ns","phase":"phase_3","mechanism":"Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue.","indications":["Acute conversion of supraventricular tachycardia to normal sinus rhythm"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Milestone Pharmaceuticals Announces FDA Approval of Etripamil for Supraventricular Tachycardia","summary":"The FDA has approved etripamil for the acute treatment of adult and pediatric patients with paroxysmal supraventricular tachycardia (PSVT).","drugName":"etripamil","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $13.4 million for the third quarter of 2023, compared to a net loss of $14.1 million for the same period in 2022.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPOHkyNWlscGo4UW5ITXdES2wwMGNDYzVFVV9MWGVreWNzekdRRTlfbUtMdlllaHRmTlRUSm1lZzloaThvVWRoMTA4cGJud3J2MXE0MXBCVjNUN2N0RVVibkhyTy1ldk9MSkZodmgyQXVjcTRhM1FIbG1SSXUzN294anNzQmNOOFo4YVdWRm5wWEo1X3JaWnExa1dzc0RBTkFoQzN0Q29WYXBjOF9ad2dHcVFscXNmQmFTYjNzR0RuV2pNQm5KNzA1RllRZw?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan","headline":"Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPekw4Y3c2Nmd3aGxITUlYeWVCdGloNmdxc19uVmxXU3hINXdOTWZzZkQxSDRlTmlLLUYya3pxajMyMm5lN2VjX2p2YWtNZzk4ZWVsRVBvekZRQUdQTV9wd1JsTm8xZlBIOUxtanEyX2gzOTFGbExBVzJvRlR6UktxTEpiLXdJTE9oSDV6VWFiT2ppTFhJWXQybWVkTjFHdFQtcWoxcTZ4WjRlUQ?oc=5","date":"2026-03-20","type":"pipeline","source":"Benzinga","summary":"Why Milestone Pharma Stock Is Taking A Dive Today - Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga","headline":"Why Milestone Pharma Stock Is Taking A Dive Today - Milestone Pharmaceuticals (NASDAQ:MIST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOUFdkY01tVUctLVZFOUhSdE9aQ2lWWkRyX2lVZU1JemNtNGRyU0NaUE9YWVphTmJZOWNlaFA3aW5vYVZBV1JfVWxVanJlWkFGWGFPMl9QN3JsN3UxRlBUSjlmQ09EQTJoM3pLZ2VKSHNPb0pIclRCODQ3aWlSdFhzak00U3F2N2RNeEE?oc=5","date":"2026-03-20","type":"earnings","source":"StocksToTrade","summary":"Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations​ - StocksToTrade","headline":"Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations​","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPblFET1pxR0REWWdKQzVheTFTMVZwWTVxUzloSi1wenNhR1NydWlzWnB2ZVBiUDYzMzY0SWxqdjd5cndrakZOMmRRS1gwYXF5S2hMTEg1X0JxV1dBQlBxa1JlS0NWWWE1Mk5nSHlCUG1JdE1ZWmxKMUd2aktwMjE4N0UtX0Y4dGY4aHdMOXVUSFFQbnYwWUs5UnhPbGs4RmVSbWtBX1pneXJka2VMWFVDNmR2VlIzeGk4QTZ0ZHh3?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan","headline":"Milestone Pharma sets Mar. 20 call to review 2025 results","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTENjOTEwTjBBNzhRUWxOMDlvbkhiMmdCZGk1MFJ3YzRreGRTZS1sYWY4SEYzVUV3WnhDc25JTDdnSFdfRG9VN09zeDJ3NFlwVHZHZkVOX3RHdlR0WlBXYnFONTE1OGUzY0R6ZmNYUmNCRjI5QmNaNG5xak16Ry1GVHhOVFZONFEzNUU0LTBXaWZrNkk4WWJZRTdfSmtXS0czUnlRelFVSnpLcVpMMWdLOTB2S0dacUR0b09nYw?oc=5","date":"2026-01-15","type":"regulatory","source":"Seeking Alpha","summary":"Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha","headline":"Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-12-17","type":"regulatory","source":"simplywall.st","summary":"Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed? - simplywall.st","headline":"Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Cha","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOaHdjLU56em55R2VLOU0weUFPOTBpV1ZFUDlqZHJNZUozMUNKUnVsWktoUW5jei1aeFkwWW5zLTA1bEd0dmtpbnI0LUJBbzVwckY0bXNqWEFNbndkUnlQRWhxTGlRMk5NVjFoSFp3ZzlkeTJnUkV5cVlYT3hNR3B1S05SMk8xZFhIOHZvZjVKbGFnWk0?oc=5","date":"2025-12-16","type":"regulatory","source":"Yahoo Finance","summary":"Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance","headline":"Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNaW5Od0NyckNBZy1vcVhrNkJndUVCanZLUm5hWUljbklyejJzbnV1WUFBZjlnMnJvckEzbTYwcGMxOFU5aUcxemo4QnNtZlFOOEx4Q0JSZDNhN2lKU21iRjUzbDAydlJHR01iN2xMTDVCaEhfclRyd3lDU1EwRjZPWXZZcXpwbUVRMjNzTGFIdnBNck82akF6RVRyTlNGUGZxQ1NabElQMUFvY1BrZ1VHVDNrcXkzN2RXQ0RFQWxLa0pWamI0UDRsekhzemZlQQ?oc=5","date":"2025-12-15","type":"regulatory","source":"TechStock²","summary":"Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - TechStock²","headline":"Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQeVY3UXNYRkNMRGdJNlNKc1Q4TV9tTTZ2cGlLVWlwUjd3ZW0wU3d0eVJMM0hKenRTYzFHaWh1S2Z5YU9ENFh3VFIxZWhnMUlySmlhcG9qUDFwNVZINFhQZTZsRDNiUXRjdW8yY0gyUnd2TWlMemJSaGhJRlR2cEszcXRsSGpTWkVhWFVERTlBVjBXbTNiY1E4QmtCLUhveWl1S09Va2JmWkJJVnV0SUlETnV0YUoyMkRBVkYyaWNDTQ?oc=5","date":"2025-12-15","type":"pipeline","source":"Seeking Alpha","summary":"Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) - Seeking Alpha","headline":"Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMzlWelZFME9mT1pBUEllZ1lXblpEaFZnMmJpMDdxaHZ6QTZ5cDQ4cEFyWkRyTEhFNzluRmtFanlyZmQ2bXpVcU1YQW56MmNNZEllSEFoUUtZRFNJUHBucHdCOWJCUG1EcXB0Y1BaZE0tcmtESVRpSVRvcTRxdDd6YTFGNWVadWZVRzluMUFISHZrYXNZaU9z?oc=5","date":"2025-11-25","type":"pipeline","source":"Yahoo Finance","summary":"Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Yahoo Finance","headline":"Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOYmVPWjFaV0dhb1ZCMzdHT0xvUV9qUHFjT204XzVZWi13enZuUDRhMElmQWNiQjN6YkE5a0pxeWFsek9kX0ttUmU3Y05YcnltUDhaN0JTX1Bsb0tOTVo2SDkyOHJzOGRfRHYydlJFVDhCc3VyS0Nwd0otOFV1dFExNXZ4QXZSMllrV0lnSnhEaUpPMkJjM0FhV3ZiQ3MyQzVYVEFyWDM5S1hSaWdKTzNhbnNtU3JhMWFkaTBGY3NSUnItTWI2eUxYdkJIUExib0pjQjdGSnlhNjlkYTFVaXNSMEwtTi1FNzNNR0xEY1BBOHJuem_SAfgBQVVfeXFMUHd4OXRoRG8yd2ZKNTROWmhScDNlUXp4QkJNam81dEQwRzlIa1NfS1VSaUItdXV0TnRHTGZXV3VpdmJ3VTRFS1psOVdwTjR1TGs0Y1FYa3dJWnBrSXV4M3FjRjQtR3RVQi1hRW9aM2JsUGswR1RpWmh0RHFiY2x2cHBmTWxlWE1ROFlFZV9pbV96TDJMRXlQdUx4Yjc3MmloN1hLSjE2SHEzVDIySmRyWnBKQ3o2bDlfZ09KRTRNS1JzSmNVVzB3WkZsZVJsVzlNbG9FdXFEd1VRVEcwM2ZQQlB6QTNPMFItWUYwaFFxb1FxZkZpVjZLc0I?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - simplywall.st","headline":"Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNdEdhazFlVk4xOFhIWHVzSlJ2cV9PcEo1dW12Vnl5VzA2LWROQlRCX25vQklxSklBRlU0alNmSS10VkEtMDlBQjlnU2JubnFvY0dyTG42NkZqeS0tbGswOFJNdmFDQ2xLU3FQenE4WFRBTGlXTndVWTd0Y3FXNU9xanZXMENZYy14OEZkNDNhZHBTNkV6LUw4UEZFd2E1ZkNETklUYTlFWG1wUTE4bVJiLVI4SzBNMEtERTVteWpsVFlWVXdrNVR1Ml83SE9SUW43YkE?oc=5","date":"2025-09-11","type":"pipeline","source":"Investing.com","summary":"Wells Fargo initiates Milestone Pharmaceuticals stock with Overweight rating - Investing.com","headline":"Wells Fargo initiates Milestone Pharmaceuticals stock with Overweight rating","sentiment":"neutral"}],"patents":[{"drugName":"etripamil","drugSlug":"etripamil","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Amgen","Bristol Myers Squibb","Pfizer"],"therapeuticFocus":["Cardiovascular","Cardiology"],"financials":{"source":"sec_edgar+yahoo","revenue":1546000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1546000},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":1000000},{"period":"2022-12-31","value":5000000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18108000,"rdSpendHistory":[{"period":"2025-12-31","value":18108000},{"period":"2024-12-31","value":14357000},{"period":"2023-12-31","value":31052000},{"period":"2022-12-31","value":39829000}],"sgaSpend":45578000,"operatingIncome":-62140000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-62140000},{"period":"2024-12-31","value":-42102000},{"period":"2023-12-31","value":-61098000},{"period":"2022-12-31","value":-59642000}],"netIncome":-63058000,"netIncomeHistory":[{"period":"2025-12-31","value":-63058000},{"period":"2024-12-31","value":-41519000},{"period":"2023-12-31","value":-59685000},{"period":"2022-12-31","value":-58388000}],"eps":-0.67,"epsHistory":[{"period":"2024-12-31","value":-0.67},{"period":"2023-12-31","value":-1.39},{"period":"2022-12-31","value":-1.38},{"period":"2021-12-31","value":-1.02}],"cash":73046000,"cashHistory":[{"period":"2025-12-31","value":73046000},{"period":"2024-12-31","value":25314000},{"period":"2023-12-31","value":13760000},{"period":"2022-12-31","value":7636000}],"totalAssets":113561000,"totalLiabilities":71792000,"totalDebt":58377000,"equity":41769000,"operatingCashflow":-49041000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-49041000},{"period":"2024-12-31","value":-28848000},{"period":"2023-12-31","value":-46424000},{"period":"2022-12-31","value":-52469000}],"capex":-302000,"capexHistory":[{"period":"2025-12-31","value":-302000},{"period":"2024-12-31","value":-33000},{"period":"2023-12-31","value":-112000},{"period":"2022-12-31","value":-272000}],"freeCashflow":-49343000,"dividendsPaid":null,"buybacks":null,"employees":38,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":13282000,"ebit":-16424000,"ebitda":-16390000,"period":"2025-12-31","revenue":1546000,"epsBasic":null,"netIncome":-17409000,"rdExpense":5521000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-17257000},{"sga":7889000,"ebit":-10955000,"ebitda":-10930000,"period":"2025-09-30","revenue":0,"epsBasic":-0.12,"netIncome":-11922000,"rdExpense":3940000,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-11829000},{"sga":8862000,"ebit":-12015000,"ebitda":-11987000,"period":"2025-06-30","revenue":0,"epsBasic":-0.2,"netIncome":-12966000,"rdExpense":3669000,"epsDiluted":-0.2,"grossProfit":null,"operatingIncome":-12531000},{"sga":15545000,"ebit":-19826000,"ebitda":-19799000,"period":"2025-03-31","revenue":0,"epsBasic":-0.31,"netIncome":-20761000,"rdExpense":4978000,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":-20523000},{"sga":8408000,"ebit":-11444000,"ebitda":-11418000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-12363000,"rdExpense":3940000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-12348000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.14,"netIncome":null,"rdExpense":null,"epsDiluted":-0.14,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.55,"previousClose":1.72,"fiftyTwoWeekHigh":3.06,"fiftyTwoWeekLow":1,"fiftyTwoWeekRange":"1.0 - 3.06","fiftyDayAverage":1.72,"twoHundredDayAverage":1.9,"beta":1.04,"enterpriseValue":-19352768,"forwardPE":-1.5,"priceToBook":4.56,"priceToSales":120.33,"enterpriseToRevenue":-12.52,"enterpriseToEbitda":0.31,"pegRatio":0,"ebitda":-62026000,"ebitdaMargin":0,"freeCashflow":-28903250,"operatingCashflow":-49041000,"totalDebt":58377000,"debtToEquity":139.8,"currentRatio":8.01,"returnOnAssets":-41.1,"returnOnEquity":-229.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":6.5,"targetHighPrice":8,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.5,"institutionHeldPercent":25,"sharesOutstanding":119637391,"floatShares":14065877,"sharesShort":7809686,"shortRatio":3.08,"shortPercentOfFloat":6.5,"epsTrailing":-0.75,"epsForward":-1.01,"revenuePerShare":0.02,"bookValue":0.34,"officers":[{"age":57,"name":"Mr. Joseph G. Oliveto M.B.A.","title":"CEO, President & Executive Director"},{"age":52,"name":"Mr. Amit  Hasija","title":"CFO & Executive VP of Corporate Development"},{"age":63,"name":"Dr. David B. Bharucha FACC, M.D., Ph.D.","title":"Chief Medical Officer"},{"age":63,"name":"Dr. Philippe  Douville M.B.A., Ph.D.","title":"Founder, Strategic Advisor & Member of Scientific Advisory Board"},{"age":44,"name":"Mr. Jeffrey  Nelson","title":"Chief Operating Officer"},{"age":47,"name":"Mr. David  Sandoval","title":"General Counsel & Chief Compliance Officer"},{"age":null,"name":"Mr. Roshan  Girglani","title":"Vice President of Marketing"},{"age":null,"name":"Mr. Jeff  Moore","title":"Vice President of Sales"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.milestonepharma.com","phone":"514 336 0444"}}